General MedicationsINTRAVENOUS, SUBCUTANEOUSStandard
AZACITIDINE
AZACITIDINE
Standard Dose
100MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview AZACITIDINE is listed in Drugs@FDA under application 217453 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient AZACITIDINE Form and strength POWDER;INTRAVENOUS, SUBCUTANEOUS - 100MG/VIAL Sponsor RELIANCE LIFE Submission history Latest submission status date: 2025-05-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview AZACITIDINE is listed in Drugs@FDA under application 217453 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient AZACITIDINE Form and strength POWDER;INTRAVENOUS, SUBCUTANEOUS - 100MG/VIAL Sponsor RELIANCE LIFE Submission history Latest submission status date: 2025-05-20 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.